VHL Gene Mutations in Renal Cell Carcinoma: Role as a Biomarker of Disease Outcome and Drug Efficacy

被引：120
作者：
Cowey, C. Lance [1 ]
Rathmell, W. Kimryn [1 ]
机构：
[1] Lineberger Canc Ctr, Chapel Hill, NC 27599 USA
来源：
CURRENT ONCOLOGY REPORTS | 2009年 / 11卷 / 02期
关键词：
TUMOR-SUPPRESSOR GENE; HIPPEL-LINDAU GENE; ENDOTHELIAL GROWTH-FACTOR; HYPOXIA-INDUCIBLE GENES; SOMATIC MUTATIONS; INTERFERON-ALPHA; CANCER; IDENTIFICATION; PROGNOSIS; THERAPY;
D O I：
10.1007/s11912-009-0015-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The therapeutic landscape for renal cell carcinoma (RCC) has changed drastically over the past several years with the emergence of molecularly targeted therapies. With previous prognostic and predictive tools based on studies of patients treated with cytokine therapies, confirmation of these prior methods and discovery of new markers in this new era of targeted therapy are of great importance. Alteration of the von Hippel-Lindau gene (VHL) by mutation, loss of heterozygosity, and promoter methylation has been found to be important to RCC pathogenesis. In this review, we discuss the potential role of VHL mutation as a prognostic and predictive marker for RCC.
引用
收藏
页码：94 / 101
页数：8
相关论文
共 48 条
  • [41] VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma
    Schraml, P
    Struckmann, K
    Hatz, F
    Sonnet, S
    Kully, C
    Gasser, T
    Sauter, G
    Mihatsch, MJ
    Moch, H
    [J]. JOURNAL OF PATHOLOGY, 2002, 196 (02) : 186 - 193
  • [42] SHUIN T, 1994, CANCER RES, V54, P2852
  • [43] Genetic and epigenetic alterations in the von Hippel-Lindau gene: The influence on renal cancer prognosis
    Smits, Kim M.
    Schouten, Leo J.
    van Dijk, Boukje A. C.
    de Kaa, Christina A. Hulsbergen-van
    Wouters, Kim A. D.
    Oosterwijk, Egbert
    van Engeland, Manon
    Van den Brandt, Piet A.
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (03) : 782 - 787
  • [44] Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy
    Upton, MP
    Parker, RA
    Youmans, A
    McDermott, DF
    Atkins, MB
    [J]. JOURNAL OF IMMUNOTHERAPY, 2005, 28 (05) : 488 - 495
  • [45] Wiesener MS, 2001, CANCER RES, V61, P5215
  • [46] Yao M, 2002, JNCI-J NATL CANCER I, V94, P1569
  • [47] Zbar B, 1996, HUM MUTAT, V8, P348, DOI 10.1002/(SICI)1098-1004(1996)8:4<348::AID-HUMU8>3.0.CO
  • [48] 2-3
12345